Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
10-14 May, 2026
Gynecology and Obstetr...Gynecology and Obstetrics
Not Confirmed
Not Confirmed
11-12 May, 2026
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
RDD
Not Confirmed
Contact SupplierRDD
Industry Trade Show
Not Confirmed
10-14 May, 2026
Gynecology and Obstetr...Gynecology and Obstetrics
Industry Trade Show
Not Confirmed
11-12 May, 2026
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Digital content
NEWS #PharmaBuzz
30 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/30/3264531/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-for-Review-of-New-Drug-Application-for-Lirafugratinib-as-Second-line-Cholangiocarcinoma-Treatment.html
30 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/30/3229623/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-Resubmission-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Systemic-Treatment-for-Unresectab.html
29 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/29/3228675/0/en/Elevar-Therapeutics-Names-Dong-Gun-Kim-CEO-as-It-Focuses-on-Post-NDA-Commercialization-Strategy.html
28 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/28/3228106/0/en/Elevar-Therapeutics-Submits-New-Drug-Application-to-FDA-for-Lirafugratinib-as-Second-Line-Treatment-Option-for-Cholangiocarcinoma.html
03 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/03/3199018/0/en/Elevar-Therapeutics-Announces-Publication-of-CARES-310-Study-Final-Analysis-in-The-Lancet-Oncology.html
22 Mar 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/fda-rejects-hengrui-elevars-pd-1-cancer-drug-combination-again
Drugs in Development
Details:
Lirafugratinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of neoplasms.
Lead Product(s): RLY-4008
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2026
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Details : Lirafugratinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2026
Details:
SHR-1210 (camrelizumab) in combination with rivoceranib (apatinib) is being evluated for the treatment of first-line therapy in patients With advanced hepatocellular carcinoma.
Lead Product(s): Camrelizumab,Apatinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Jiangsu Hengrui Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2025
Lead Product(s) : Camrelizumab,Apatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Rejects Hengrui, Elevar's PD-1 Cancer Drug Combo—Again
Details : SHR-1210 (camrelizumab) in combination with rivoceranib (apatinib) is being evluated for the treatment of first-line therapy in patients With advanced hepatocellular carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 21, 2025
Details:
The agreement grants Elevar worldwide rights to develop and commercialize RLY-4008 (lirafugratinib), an oral small molecule inhibitor of FGFR2 being developed for FGFR2-driven cholangiocarcinoma.
Lead Product(s): RLY-4008
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Recipient: Relay Therapeutics
Deal Size: $500.0 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement December 03, 2024
Lead Product(s) : RLY-4008
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Relay Therapeutics
Deal Size : $500.0 million
Deal Type : Licensing Agreement
Elevar & Relay Therapeutics License Lirafugratinib for FGFR2 Cancer & Solid Tumors
Details : The agreement grants Elevar worldwide rights to develop and commercialize RLY-4008 (lirafugratinib), an oral small molecule inhibitor of FGFR2 being developed for FGFR2-driven cholangiocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $75.0 million
December 03, 2024
Details:
Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Lead Product(s): Apatinib,Camrelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2024
Elevar Resubmits Rivoceranib NDA for Unresectable Hepatocellular Carcinoma
Details : Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
Details:
Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Lead Product(s): Apatinib,Camrelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Elevar Resubmits NDA for Camrelizumab plus Rivoceranib in uHCC
Details : Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2024
Details:
Apatinib (rivoceranib), a small-molecule TKI, is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Lead Product(s): Apatinib,Camrelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2024
Elevar Therapeutics Receives EMA Orphan Designation for Hepatocellular Carcinoma
Details : Apatinib (rivoceranib), a small-molecule TKI, is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2024
Details:
Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Lead Product(s): Apatinib,Camrelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2024
Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment
Details : Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2024
Details:
Aitan (rivoceranib), a VEGFR-2 inhibitor, is being investigated with SHR-1210 (camrelizumab) and is already approved in China. The company has resubmitted its NDA to the FDA for unresectable HCC.
Lead Product(s): Apatinib,Camrelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Jiangsu Hengrui Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2024
Lead Product(s) : Apatinib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment
Details : Aitan (rivoceranib), a VEGFR-2 inhibitor, is being investigated with SHR-1210 (camrelizumab) and is already approved in China. The company has resubmitted its NDA to the FDA for unresectable HCC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2024
Details:
Rivoceranib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Esthesioneuroblastoma, Olfactory.
Lead Product(s): Apatinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: MD Anderson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2024
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
Details : Rivoceranib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Esthesioneuroblastoma, Olfactory.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 13, 2024
Details:
Under the agreement, Elevar gain rights to commercialize and develop Hengrui’s anti-PD-1 antibody SHR-1210 (camrelizumab), in combination with rivoceranib (aka apatinib) for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.
Lead Product(s): Camrelizumab,Apatinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Jiangsu Hengrui Medicine
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 17, 2023
Lead Product(s) : Camrelizumab,Apatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Jiangsu Hengrui Medicine
Deal Size : $600.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Elevar gain rights to commercialize and develop Hengrui’s anti-PD-1 antibody SHR-1210 (camrelizumab), in combination with rivoceranib (aka apatinib) for unresectable hepatocellular carcinoma worldwide, excluding Greater China Regio...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
